US FDA’s Coronavirus Workload Shifting Beyond Idea Stage
Executive Summary
Pre-IND inquiries are slowing and the FDA says more late-stage development work is coming.
You may also be interested in...
US FDA Pandemic Performance: On-Time Decision Rates Improve; COVID Applications, Supplements Drop
Biosimilars continue their erratic behavior, with the low numbers driving big swings.
COVID-19 Supplement Approvals Jump, Some On-Time Decision Rates Slip For US FDA
In FY '21 third quarter, on-time decision rate improved for generics and biosimilars, but dropped again for new drug applications.
The COVID Boom: CBER Receives More INDs in One Quarter Than The Previous 30 Combined
Bubble was short-lived, but still could create workload problems for the US FDA as it navigates the end of the coronavirus pandemic.